It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Serum brain-derived neurotrophic factor (BDNF) reflects state changes in mood disorders. But its relation to brain changes in depression has rarely been investigated in humans. We assessed the association between serum BDNF, cortical thickness, or gray matter volume in 20 subjects with a minor depressive episode and 40 matched healthy subjects. Serum BDNF positively correlated with cortical thickness and volume in multiple brain regions in the minor depression group: the bilateral medial orbitofrontal cortex and rostral anterior cingulate cortex, left insula, and cingulum, right superior frontal gyrus, and other regions—regions typically affected by major depression. Interestingly, these correlations were driven by subjects with first episode depression. There was no significant association between these imaging parameters and serum BDNF in the healthy control group. Interaction analyses supported this finding. Our findings point to a specific association between serum BDNF and magnetic resonance imaging parameters in first-episode minor depression in a region- and condition-dependent manner. A positive correlation between serum BDNF and structural gray matter estimates was most consistently observed for cortical thickness. We discuss why cortical thickness should be preferred to volumetric estimates for such analyses in future studies. Results of our pilot study have to be proven in future larger-scale studies yielding higher statistical power.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028); University of Leipzig, Clinic for Psychiatry and Psychotherapy, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, Clinic for Cognitive Neurology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
2 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028); University of Leipzig, CRC Obesity Mechanisms, Subproject A1, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
3 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028)
4 University of Leipzig, Clinic for Psychiatry and Psychotherapy, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
5 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
6 University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Leipzig University, Institute of Social Medicine, Occupational Health and Public Health (ISAP), Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
7 University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Leipzig University, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
8 Leipzig University, Department of Neuroradiology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
9 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Humboldt-University of Berlin, Berlin School of Mind and Brain and the Mind-Brain Institute, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639)
10 University of Leipzig, Clinic for Psychiatry and Psychotherapy, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Technical University of Dresden, Department of Psychiatry and Psychotherapy, University Affiliated Hospital Arnsdorf, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
11 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (GRID:grid.419524.f) (ISNI:0000 0001 0041 5028); University of Leipzig, LIFE—Leipzig Research Center for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, Clinic for Cognitive Neurology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)